Zepbound for sleep apnea: the March 2024 FDA indication that changes coverage

TLDR. In December 2024 the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first GLP-1 indication for OSA. The trial (SURMOUNT-OSA) showed roughly a 60 percent reduction in apnea-hypopnea index (AHI) at 52 weeks alongside the expected weight loss. Insurance coverage shifted: many commercial plans now cover Zepbound under the OSA indication with PA criteria similar to obesity but with sleep study documentation required. The path opens GLP-1 access for patients whose plan does not cover obesity alone but does cover OSA.

In December 2024 the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity. This was the first time a GLP-1 medication had been approved with an OSA-specific indication. For tens of thousands of patients with both OSA and obesity, this changed the insurance-coverage equation dramatically. Here is what the indication means in practice.

What the trial showed

The SURMOUNT-OSA trial (published NEJM 2024) enrolled 469 adults with moderate-to-severe OSA and obesity. After 52 weeks on tirzepatide 15 mg weekly:

• Mean reduction in Apnea-Hypopnea Index (AHI): 25-30 events/hour, vs ~5 in placebo
• 43% of patients on tirzepatide achieved disease remission (AHI < 5)
• Mean weight loss: 18-20% of body weight
• Daytime sleepiness, blood pressure and quality-of-life metrics all improved

The FDA approved Zepbound for OSA in adults with obesity (BMI ≥ 30) in December 2024 based on this trial.

Why the indication matters for insurance

Before the OSA indication, Zepbound was approved only for chronic weight management. Insurance plans that explicitly excluded weight-loss medications would deny Zepbound coverage even for severe OSA patients. The new indication creates a separate coverage path:

• If your plan excludes weight-loss medications but covers sleep-disorder treatments, Zepbound is now potentially covered under the OSA indication
• Prior authorization requires documented OSA diagnosis (sleep study showing AHI ≥ 15 for moderate, AHI ≥ 30 for severe) plus obesity
• CPAP-intolerant or CPAP-refractory patients are particularly strong candidates for the indication

The PA paperwork required

For the OSA indication, prior authorization typically requires:

• Sleep study (polysomnography) confirming moderate or severe OSA
• BMI ≥ 30
• Documentation of CPAP trial OR documented CPAP intolerance
• Prescribing clinician with ability to monitor OSA outcomes (most obesity-medicine and sleep-medicine clinicians qualify)

If you have an established sleep-medicine relationship, the PA paperwork is often easier than the standard obesity PA because the OSA diagnosis is already documented.

Who this changes things for

Three patient cohorts saw their access to GLP-1 expand meaningfully:

• Patients on weight-loss-excluded employer plans: many ACA-marketplace and self-insured employer plans explicitly exclude weight-loss drugs. The OSA indication routes around that exclusion.
• CPAP-intolerant OSA patients: until 2024, the standard alternatives (mouth devices, surgery) had limited efficacy. Zepbound is now an evidence-backed option.
• Medicare Part D members with OSA: Medicare Part D now lists Zepbound under the OSA indication on most plans' formularies. Coverage at $50-$150/month copay tier.

Combined Wegovy CV + Zepbound OSA = broader Medicare access

For Medicare patients, the combination of indications widens the coverage net considerably:

• Established cardiovascular disease → Wegovy under CV indication
• Moderate-severe OSA → Zepbound under OSA indication
• Type 2 diabetes → Ozempic or Mounjaro under T2D indication

A Medicare patient with any one of these qualifying conditions has Part D access to a covered GLP-1 in 2026. See our Medicare CV rankings and Medicare T2D rankings.

Programs equipped for OSA-indication prescribing

Programs that handle sleep-medicine-adjacent prescribing well:

• Form Health, obesity-medicine specialists who'll document the OSA-plus-obesity case correctly
• Knownwell, primary-care integrated, can coordinate with your sleep-medicine clinician
• 9amHealth, cardiometabolic focus, common comorbidity overlap with OSA
• PlushCare, runs the PA with sleep-study documentation

If you have known OSA and your current obesity PA was previously denied, ask your prescriber to re-submit under the OSA indication. The criteria are different and the approval rate is meaningfully higher.

For the broader prior-authorization playbook, see our PA step-by-step.

Frequently asked questions

Does Zepbound treat obstructive sleep apnea?

Yes, when prescribed under the December 2024 FDA-approved OSA indication for adults with obesity. The SURMOUNT-OSA trial showed roughly a 60 percent reduction in apnea-hypopnea index (AHI) at 52 weeks alongside the expected weight loss. The mechanism is mostly the weight loss (less airway compression during sleep) but the magnitude of AHI improvement is larger than weight loss alone usually produces, suggesting additional pathway effects.

What does the OSA indication mean for insurance coverage?

Many commercial plans now cover Zepbound under the OSA indication with PA criteria similar to obesity but with sleep-study documentation required (AHI of 15 or higher for moderate-to-severe OSA). The shift is meaningful: plans that exclude weight-loss medication can sometimes cover Zepbound under the OSA indication. Medicare Part D does not cover OSA-only Zepbound.

Do I still need a CPAP machine if I take Zepbound?

Yes, in most cases. The OSA indication does not replace CPAP; it complements weight loss as part of OSA management. Patients on Zepbound may eventually have low enough AHI to discontinue CPAP after meaningful weight loss, but that decision belongs to your sleep-medicine physician based on a repeat sleep study. Stopping CPAP prematurely is unsafe.

Does Wegovy work for OSA too?

Not under the FDA-approved indication. Wegovy does not have an OSA-specific approval. The expectation is that semaglutide-induced weight loss reduces AHI similarly to tirzepatide-induced weight loss, but the FDA-recognized evidence is currently tirzepatide-only. Coverage paths for OSA run through Zepbound, not Wegovy.

What documentation do I need for OSA-indication PA?

Sleep study (in-lab polysomnography or qualified home sleep test) showing AHI of 15 or higher (moderate-to-severe), BMI of 30 or higher, and prescriber attestation that the patient is appropriate for chronic anti-obesity pharmacotherapy. Some plans add lifestyle-modification documentation similar to obesity PA. The OSA path is generally less restrictive on lifestyle documentation than pure obesity PA.